+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Epinephrine exerts opposite effects on peripheral glucose disposal and glucose-stimulated insulin secretion. A stable label intravenous glucose tolerance test minimal model study



Epinephrine exerts opposite effects on peripheral glucose disposal and glucose-stimulated insulin secretion. A stable label intravenous glucose tolerance test minimal model study



Diabetes 45(10): 1373-1378



Epinephrine (EPI) plays a pivotal role in regulating glucose metabolism both in splanchnic and peripheral tissues. Nevertheless, previous studies did not clarify the mechanisms by which EPI affect both glucose disposal processes in peripheral tissues and beta-cell secretion. The aim of this study was to investigate, in six normal volunteers, the effects of elevated EPI concentration on peripheral glucose disposal and insulin secretion by using the stable labeled (either (6,6-2H-2)or (2-2H-1)glucose) intravenous glucose tolerance test (IVGTT) in conjunction with the minimal models of labeled glucose disappearance and C-peptide secretion. Elevated plasma EPI concentration significantly decreased glucose effectiveness (S-G*) by 29% (0.0059 +- 0.0013 vs. 0.0083 +- 0.0011 min-1, P lt 0.05), and even more, 61%, insulin sensitivity (S-I*); (22 +- 6 times 10-4 vs. 54 +- 20 times 10-4 min-1 cntdot pmol cntdot l-1; P lt 0.01). These findings are not due to an isotopic effect induced by an enhanced glycogen breakdown, because the (2-2H-1)glucose tracer, which is not incorporated into glycogen, gave results similar to those of (6,6-2H-2)glucose tracer. No differences were observed in first phase cell sensitivity, PHI-1, in the EPI study (199 +- 91 vs. 245 +- 144 10-9, NS), but there was a significant increase in the second-phase cell sensitivity to glucose PHI-2, (15.2 +- 1.7 vs. 17.7 +- 4.4 10-9 cntdot min-1, P lt 0.05). In conclusion, EPI selectively impairs peripheral glucose metabolism because of its unique ability to simultaneously and independently decrease glucose effectiveness and insulin sensitivity. Furthermore, EPI enhances PHI-2, the ratio between the C-peptide amount secreted during the second phase and the area under the curve of the glucose signal, indicating that the observed increase of C-peptide concentration is due not only to the augmented glucose signal but also to a specific EPI-mediated enhancement of beta-cell responsivity to glucose.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 008618807

Download citation: RISBibTeXText

PMID: 8826974

DOI: 10.2337/diab.45.10.1373


Related references

Glucose metabolism in severe malaria: minimal model analysis of the intravenous glucose tolerance test incorporating a stable glucose label. Metabolism: Clinical and Experimental 46(12): 1435-1440, 1997

Stable-label intravenous glucose tolerance test minimal model. Diabetes 38(8): 1048-1055, 1989

Plasma leptin concentrations do not appear to decrease insulin-mediated glucose disposal or glucose-stimulated insulin secretion in women with normal glucose tolerance. Diabetes 47(2): 244-247, 1998

Glucose disposal minimal model insulin sensitivity index from labelled meal glucose tolerance test. Diabetes 50(Suppl. 2): A65, 2001

Dual Actions of Apolipoprotein A-I on Glucose-Stimulated Insulin Secretion and Insulin-Independent Peripheral Tissue Glucose Uptake Lead to Increased Heart and Skeletal Muscle Glucose Disposal. Diabetes 65(7): 1838-1848, 2016

Comparison of estimates of insulin sensitivity and B-cell function derived from the oral glucose tolerance test versus the intravenous glucose tolerance test and minimal model. Journal of Investigative Medicine 47(2): 77A, 1999

Resistance exercise and growth hormone administration in older men: Effects on insulin sensitivity and secretion during a stable-label intravenous glucose tolerance test. Metabolism Clinical and Experimental 45(2): 254-260, 1996

The intravenous prandial glucose tolerance test minimal model for measuring glucose effectiveness and insulin sensitivity. Diabetologia 42(Suppl. 1): A186, 1999

Studies on lipid and carbohydrate metabolism in the rat. Effects of diet on body composition, plasma glucose and insulin concentrations, insulin secretion in vitro and tolerance to intravenous glucose and intravenous glucose and intravenous insulin. Australian Journal of Experimental Biology and Medical Science 50(3): 267-287, 1972

Insulin sensitivity and glucose clearance quantified in humans from labelled intravenous glucose tolerance test and minimal model. Diabetologia 30(7): 506A, 1987

Estimation of insulin sensitivity and glucose clearance from minimal model new insights from labeled intravenous glucose tolerance test. American Journal of Physiology 250(5 Part 1): E591-E598, 1986

The intravenous glucose tolerance test in cannulated Wistar rats: a robust method for the in vivo assessment of glucose-stimulated insulin secretion. Journal of Pharmacological and Toxicological Methods 57(2): 106-113, 2008

Evaluation of insulin sensitivity and glucose effectiveness during a standardized breakfast test: comparison with the minimal model analysis of an intravenous glucose tolerance test. Metabolism: Clinical and Experimental 55(5): 676-690, 2006

Insulin sensitivity and glucose clearance quantified from labeled intravenous glucose tolerance test via revisited minimal model technique. Diabetes Research & Clinical Practice (Suppl. 1): S104, 1985

Application of the intravenous glucose tolerance test and the minimal model to patients with insulinoma: insulin sensitivity (Si) and glucose effectiveness (Sg) before and after surgical excision. Clinical Endocrinology 70(1): 47-52, 2009